Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

Autor: Claire Gallois, Qian Shi, Jeffrey P. Meyers, Timothy Iveson, Steven R. Alberts, Aimery de Gramont, Alberto F. Sobrero, Daniel G. Haller, Eiji Oki, Anthony Frank Shields, Richard M. Goldberg, Rachel Kerr, Sara Lonardi, Greg Yothers, Caroline Kelly, Ioannis Boukovinas, Roberto Labianca, Frank A. Sinicrope, Ioannis Souglakos, Takayuki Yoshino, Jeffrey A. Meyerhardt, Thierry André, Demetris Papamichael, Julien Taieb

Publikováno v: Journal of Clinical Oncology. 41:803-815

PURPOSE Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to whether early discontinuation of all treatment (ETD) or early discont

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41a4c10167bb6eb8ddf701696c2c97fa
https://doi.org/10.1200/jco.21.02726

Supplemental Tables and Figures from Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Autor: Scott D. Patterson, Roger Sidhu, Andre S. Jung, Jan-Henrik Terwey, Reija Koukakis, Hua Yu, Pei He, Eric Van Cutsem, Laslo Roman, Tudor E. Ciuleanu, Gregory Wilson, Andrew H. Strickland, Cornelis J.A. Punt, Florian Lordick, Emily Chan, Thierry André, Yevhen Hotko, Michel Ducreux, Alberto F. Sobrero, Andrés Cervantes, Timothy J. Price, Kelly S. Oliner, Marc Peeters

Contains: Table S1. RAS and BRAF Mutation Status Table S2. Objective Response Rate in Patients with Mutated RAS Table S3. Depth of Response and Early Tumor Response in Wild-type KRAS Exon 2 Patients Figure S1. Disposition of patients in the study and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a270e11af1fd12d264083118e64d68d8
https://doi.org/10.1158/1078-0432.22460478

Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study

Autor: Alberto F. Sobrero, Arvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, Elena Elez, Takayuki Yoshino, James C. Yao, Pilar Garcia-Alfonso, Judit Kocsis, Antonio Cubillo, Andrea Sartore-Bianchi, Taroh Satoh, Violaine Randrian, Jiri Tomasek, Geoff Chong, Zhao Yang, William R. Schelman, Marek K. Kania, Josep Tabernero, Cathy Eng

Publikováno v: Journal of Clinical Oncology. 41:67-67

67 Background: The global phase 3 FRESCO-2 study, (NCT04322539) demonstrated that fruquintinib (F) vs placebo (P) significantly improved OS (HR=0.66 [95% CI: 0.55-0.80]; p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da2e330b694e0e57a4970b515ed8d2af
https://doi.org/10.1200/jco.2023.41.4_suppl.67

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials

Autor: Nadine J McCleary, William S Harmsen, Ellana Haakenstad, James M Cleary, Jeffrey A Meyerhardt, John Zalcberg, Richard Adams, Axel Grothey, Alberto F Sobrero, Eric Van Cutsem, Richard M Goldberg, Marc Peeters, Josep Tabernero, Matt Seymour, Leonard B Saltz, Bruce J Giantonio, Dirk Arnold, Mace L Rothenberg, Miriam Koopman, Hans-Joachim Schmoll, Henry C Pitot, Paulo M Hoff, Niall Tebbutt, Gianluca Masi, John Souglakos, Carsten Bokemeyer, Volker Heinemann, Takayuki Yoshino, Benoist Chibaudel, Aimery deGramont, Qian Shi, Stuart M Lichtman

Publikováno v: JNCI Cancer Spectrum
Scientia

Background We evaluated the time to progression (TTP) and survival outcomes of second-line therapy for metastatic colorectal cancer among adults aged 70 years and older compared with younger adults following progression on first-line clinical trials.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6e091b03de42d1bfb4022d0b67dd77a
https://pubmed.ncbi.nlm.nih.gov/35603849

Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology

Autor: Richard M Goldberg, Richard Adams, Marc Buyse, Cathy Eng, Axel Grothey, Thierry André, Alberto F Sobrero, Stuart M Lichtman, Al B Benson, Cornelis J A Punt, Tim Maughan, Tomasz Burzykowski, Dirkje Sommeijer, Everardo D Saad, Qian Shi, Elisabeth Coart, Benoist Chibaudel, Miriam Koopman, Hans-Joachim Schmoll, Takayuki Yoshino, Julien Taieb, Niall C Tebbutt, John Zalcberg, Josep Tabernero, Eric Van Cutsem, Alastair Matheson, Aimery de Gramont

Publikováno v: Goldberg, R M, Adams, R, Buyse, M, Eng, C, Grothey, A, André, T, Sobrero, A F, Lichtman, S M, Benson, A B, Punt, C J A, Maughan, T, Burzykowski, T, Sommeijer, D, Saad, E D, Shi, Q, Coart, E, Chibaudel, B, Koopman, M, Schmoll, H-J, Yoshino, T, Taieb, J, Tebbutt, N C, Zalcberg, J, Tabernero, J, van Cutsem, E, Matheson, A & de Gramont, A 2022, ' Clinical Trial Endpoints in Metastatic Cancer : Using Individual Participant Data to Inform Future Trials Methodology ', Journal of the National Cancer Institute, vol. 114, no. 6, pp. 819-828 . https://doi.org/10.1093/jnci/djab218
J Natl Cancer Inst

Meta-analysis based on individual participant data (IPD) is a powerful methodology for synthesizing evidence by combining information drawn from multiple trials. Hitherto, its principal application has been in questions of clinical management, but an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::823bc6d2119e00deb47545df7ec4bdd5
http://hdl.handle.net/1942/37076